This website is intended for US Healthcare Professionals.

CONTact Your MSL
Back to Congresses

ACCP

  • September 10 -
  • 12, 2023
  •  |
  • Bellevue, WA

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Presentation
Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers
J Alicea et al.
View Material
Presentation
The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers
J Alicea et al.
View Material
Presentation
The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy Volunteers
J Alicea et al.
View Material

Arvinas Oncology Medical

You are now leaving arvinasoncologymedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP